Publicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Santiago (13)

2022

  1. Correction: Chaparro et al. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study (J. Clin. Med., (2021), 10, (2885), 10.3390/jcm10132885)

    Journal of Clinical Medicine

  2. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 3, pp. 165-176

2021

  1. Incidence, clinical characteristics and management of inflammatory bowel disease in spain: Large-scale epidemiological study

    Journal of Clinical Medicine, Vol. 10, Núm. 13

  2. Recommendations of the Spanish Working Group on Crohn's disease and Ulcerative Colitis (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa — GETECCU) on dysplasia screening in inflammatory bowel disease patients

    Gastroenterologia y Hepatologia, Vol. 44, Núm. 6, pp. 435-447

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients

    Digestive Diseases and Sciences, Vol. 64, Núm. 3, pp. 846-854

2015

  1. Clinical, biological, and endoscopic responses to adalimumab in antitumor necrosis factor-naive Crohn's disease: Predictors of efficacy in clinical practice

    European Journal of Gastroenterology and Hepatology, Vol. 27, Núm. 4, pp. 430-435

  2. Exome-wide pharmacogenomic analysis of response to thiopurines in inflammatory bowel disease patients

    Current Pharmacogenomics and Personalized Medicine, Vol. 13, Núm. 1, pp. 61-67

  3. Influence of urban/rural and coastal/inland environment on the prevalence, phenotype, and clinical course of inflammatory bowel disease patients from northwest of Spain: A cross-sectional study

    European Journal of Gastroenterology and Hepatology, Vol. 27, Núm. 9, pp. 1030-1037

2013

  1. New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients

    Pharmacogenomics, Vol. 14, Núm. 6, pp. 631-640

2011

  1. A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving azathioprine

    Journal of Gastrointestinal and Liver Diseases, Vol. 20, Núm. 3, pp. 247-253

2010

  1. Clinical practice in Crohn's disease in bordering regions of two countries: Different medical options, distinct surgical events

    Journal of Crohn's and Colitis, Vol. 4, Núm. 3, pp. 301-311

  2. Ulcerative colitis in northern Portugal and Galicia in Spain

    Inflammatory Bowel Diseases, Vol. 16, Núm. 7, pp. 1227-1238